BioAge Labs, Inc. BIOA
5.64 USD -0.23 (-3.91%)
Nov 12, 2026, 1:55 PM EST
5.47 Day range 5.87
4.81 52-week range 25.96
- YTD
- -57.36%
- 1 year
- -29.58%
Benzinga news
benzinga.com Piper Sandler Maintains Overweight on Bioage Labs, Lowers Price Target to $40 Piper Sandler analyst Yasmeen Rahimi maintains Bioage Labs (NASDAQ:BIOA) with a Overweight and lowers the price target from $73 to $40.
benzinga.com Bioage Labs Q3 EPS $(0.73) Misses $(0.59) Estimate, Sales $298.000K Miss $1.644M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.73) per share which missed the analyst consensus estimate of $(0.59) by 23.73 percent. This is a 30.36 percent decrease over losses of…
benzinga.com BioArctic AB Announces Novartis Terminates Their 2025 Option, Collaboration And License Deal; BioArctic To Retain Full $30M Upfront Payment BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that Novartis Pharma AG has notified BioArctic that it has decided to terminate the Option, Collaboration and License Agreement entered…
benzinga.com UBS Initiates Coverage On Bioage Labs with Neutral Rating, Announces Price Target of $8 UBS analyst Alice Nettleton initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Neutral rating and announces Price Target of $8.
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…- benzinga.com BioAge Labs Doses First Patient In Its Phsae 2 Study Of BGE-102 To Treat Diabetic Macular Edema BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge" or the "Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for cardiometabolic diseases by targeting the…
- benzinga.com Bioage Labs Q2 EPS $(0.58) Beats $(0.60) Estimate, Sales $2.451M Beat $1.920M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.58) per share which beat the analyst consensus estimate of $(0.60) by 3.33 percent. This is a 3.33 percent increase over losses of $(0.60)…
- benzinga.com Needham Maintains Buy on Bioage Labs, Lowers Price Target to $35 Needham analyst Joseph Stringer maintains Bioage Labs (NASDAQ:BIOA) with a Buy and lowers the price target from $50 to $35.
benzinga.com Why Is BioAge Labs Stock Sinking Friday? BioAge Labs stock plummeted as failed Phase 3 ZEUS trial data from Novo Nordisk sparked broad concerns for NLRP3-targeting therapies.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Replimune Group (NASDAQ:REPL) stock rose 96.1% to $10.61 during Friday's regular session. SCYNEXIS (NASDAQ:SCYX) stock moved upwards by 22.54% to $4.57. The market value of their outstanding…
benzinga.com Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat Earnings US stocks rise, Nasdaq up 300 points. Dow up 0.36%, Nasdaq up 1.31%, S&P 500 up 0.65%. Amazon shares jump 14% after posting strong Q2 results.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…
benzinga.com BioAge Labs Doses First Participant Dosed In QUELL-CV Randomized, double-blind, placebo-controlled, dose-ranging trial evaluating three once-daily oral doses of BGE-102 in participants with elevated systemic inflammation and additional cardiovascular…
benzinga.com This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday Top Wall Street analysts changed outlook on top names. See analyst ratings page for upgrades, downgrades, and initiations. Check out what analysts think of GE stock.
benzinga.com Roth Capital Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $36 Roth Capital analyst Adam Walsh initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $36.
benzinga.com This CoinShares Analyst Begins Coverage On A Bullish Note; Here Are Top 2 Initiations For Wednesday Wall Street analysts changed outlook on top stocks. Check our analyst ratings page for all changes. See opinions on CSHR, BIOA.- benzinga.com BTIG Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $40 BTIG analyst Thomas Shrader initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $40.
benzinga.com Bioage Labs Q1 EPS $(0.52) Beats $(0.64) Estimate, Sales $2.772M Beat $1.083M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.52) per share which beat the analyst consensus estimate of $(0.64) by 18.75 percent. This is a 44.44 percent decrease over losses of $(0.36)…
benzinga.com BioAge Labs Stock Gains After Positive Early Data And Pipeline Plans BioAge Labs says BGE-102 Phase 1 data show strong hsCRP reductions at 60 mg and 120 mg; analysts maintain Buy ratings with higher targets.
benzinga.com Fastenal, Replimune Group, Children's Place And Other Big Stocks Moving Lower In Monday's Pre-Market Session U.S. stock futures lower, with Dow futures down 150 points. Fastenal shares dip 4% after meeting earnings estimate. Other stocks also down.
benzinga.com This Honeywell Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday Wall Street analysts change outlook on top names. Check analyst ratings page for upgrades, downgrades, and initiations. See others' views on these stocks.- benzinga.com Needham Initiates Coverage On Bioage Labs with Buy Rating, Announces Price Target of $50 Needham analyst Joseph Stringer initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Buy rating and announces Price Target of $50.
- benzinga.com Bioage Labs Q4 EPS $(0.72) Beats $(0.73) Estimate, Sales $3.078M Beat $1.915M Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.72) per share which beat the analyst consensus estimate of $(0.73) by 1.37 percent. This is a 22.03 percent decrease over losses of $(0.59)…
- benzinga.com Citigroup Maintains Buy on Bioage Labs, Raises Price Target to $52 Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and raises the price target from $15 to $52.
benzinga.com This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - benzinga.com Oppenheimer Initiates Coverage On Bioage Labs with Outperform Rating, Announces Price Target of $60 Oppenheimer analyst Jay Olson initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Outperform rating and announces Price Target of $60.
benzinga.com This Palantir Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday 
benzinga.com Jefferies Upgrades Bioage Labs to Buy, Raises Price Target to $62 Jefferies analyst Roger Song upgrades Bioage Labs (NASDAQ:BIOA) from Hold to Buy and raises the price target from $9 to $62.- benzinga.com Piper Sandler Initiates Coverage On Bioage Labs with Overweight Rating, Announces Price Target of $73 Piper Sandler analyst Yasmeen Rahimi initiates coverage on Bioage Labs (NASDAQ:BIOA) with a Overweight rating and announces Price Target of $73.
- benzinga.com Reported Earlier, BioAge Prices Upsized $115M Public Offering Of 5.9M Shares At $19.50 Per Share BioAge intends to use the net proceeds from the proposed offering, together with its existing cash, cash equivalents and marketable securities, to fund research, clinical and process development and…
benzinga.com Netflix, Erasca, Kraft Heinz And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - benzinga.com BioAge Labs Announces Up To $75M Common Stock Offering BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", "the Company"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com BioAge Labs Expands BGE-102 Development Program Into Ophthalmology, With Initial Proof-Of-Concept Study In Patients With Diabetic Macular Edema BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapiesGrowing preclinical and…
benzinga.com BioAge Labs Announces Additional Interim Data From Ongoing Phase 1 Clinical Trial Evaluating BGE-102, Brain-Penetrant Small Molecule NLRP3 Inhibitor For Treatment Of Patients With Cardiovascular Risk Factors First BGE-102 MAD cohort completed in obese individuals with elevated hsCRP receiving 120 mg QD; demonstrated rapid and profound reduction in inflammatory markersBGE-102 achieved 86% reduction in…- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Why Penguin Solutions Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket 
benzinga.com Dynavax Technologies, Omeros, Agios Pharmaceuticals, Nike And Other Big Stocks Moving Higher On Wednesday - benzinga.com Morgan Stanley Upgrades Bioage Labs to Equal-Weight, Raises Price Target to $12 Morgan Stanley analyst Jeffrey Hung upgrades Bioage Labs (NASDAQ:BIOA) from Underweight to Equal-Weight and raises the price target from $5 to $12.
benzinga.com Donaldson Posts Upbeat Results, Joins Science Applications International, Descartes Systems, Dollar General And Other Big Stocks Moving Higher On Thursday - benzinga.com BioAge Labs Data From BGE-102 Study Shows Well-Tolerance, Strong Target Engagement In Patients With Cardiovascular Risk Factors BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge"), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today…
- benzinga.com Bioage Labs Q3 EPS $(0.56) Beats $(0.58) Estimate, Sales $2.054M Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.56) per share which beat the analyst consensus estimate of $(0.58) by 3.45 percent. This is a 91.64 percent increase over losses of $(6.70)…
- benzinga.com Citigroup Maintains Buy on Bioage Labs, Raises Price Target to $15 Citigroup analyst Samantha Semenkow maintains Bioage Labs (NASDAQ:BIOA) with a Buy and raises the price target from $10 to $15.
- benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com This Badger Meter Analyst Turns Bullish; Here Are Top 4 Upgrades For Wednesday - benzinga.com Citigroup Upgrades Bioage Labs to Buy, Raises Price Target to $10 Citigroup analyst Samantha Semenkow upgrades Bioage Labs (NASDAQ:BIOA) from Neutral to Buy and raises the price target from $5 to $10.
- benzinga.com BioAge Labs Announces First Participant Dosed In Phase 1 Clinical Trial Evaluating BGE-102, Orally Available Small Molecule NLRP3 Inhibitor For Treatment Of Obesity First-in-human study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of BGE-102, an orally available small molecule with potential best-in-class profileInitial development…
- benzinga.com Bioage Labs Q2 EPS $(0.60) Misses $(0.45) Estimate Bioage Labs (NASDAQ:BIOA) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.45) by 33.33 percent.
- benzinga.com Reported Saturday, BioAge Labs Presents Preclinical Data Showing APJ Agonism Enhances Glycemic Control And Cardioprotection In Diabetic Obesity And HFpEF Treatment with apelin receptor agonist enhanced glycemic control and demonstrated cardioprotective effects, with additive benefits observed in combination with incretin therapyData support…